HUTCHMED (00013) to Hold Expert Interpretation Meeting to Discuss Latest Clinical Data on Savolitinib for Non-Small Cell Lung Cancer

HUTCHMED (00013) has announced that it will jointly hold an online expert interpretation meeting for analysts and investors with Citigroup Global Markets Asia Limited (Citi) to discuss the latest Phase III clinical data on savolitinib for the treatment of MET-driven non-small cell lung cancer recently presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress. The online meeting will be held on Thursday, November 5, 2026, at 4:30 p.m. Hong Kong Time / 8:30 a.m. Greenwich Mean Time / 3:30 a.m. Eastern Time. The discussion will feature Professor Wu Yilong, principal investigator of the SANOVO study, as the keynote speaker, who will share professional insights on the latest clinical data and treatment strategies for MET-driven non-small cell lung cancer. Dr. Su Weiguo, Chief Executive Officer (currently on leave) and Chief Scientific Officer of HUTCHMED, will also participate in the panel discussion, comprehensively integrating data from the SANOVO China study and the SAFFRON global study to discuss in depth the development progress and global regulatory registration prospects of savolitinib. The meeting will be moderated by Mr. Peng Yingqi, Asia Healthcare Research Analyst at Citi.